PE20221263A1 - Agentes de union a ilt3 y metodos de uso de los mismos - Google Patents
Agentes de union a ilt3 y metodos de uso de los mismosInfo
- Publication number
- PE20221263A1 PE20221263A1 PE2022001110A PE2022001110A PE20221263A1 PE 20221263 A1 PE20221263 A1 PE 20221263A1 PE 2022001110 A PE2022001110 A PE 2022001110A PE 2022001110 A PE2022001110 A PE 2022001110A PE 20221263 A1 PE20221263 A1 PE 20221263A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- variable region
- chain variable
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a un agente de union que comprende: (a) una region variable de cadena pesada que comprende una region variable de cadena pesada CDR1 que comprende la secuencia de aminoacidos GFTFSSYGMS (SEQ ID NO:27), una region variable de cadena pesada CDR2 que comprende la secuencia de aminoacidos TISGGGSYTNYPDSVKG (SEQ ID NO:28), y una region variable de cadena pesada CDR3 que comprende la secuencia de aminoacidos REWRMTLYAMDY (SEQ ID NO:29) o REWRYTLYAMDY (SEQ ID NO:105), y (b) una region variable de cadena ligera que comprende una region variable de cadena ligera CDR1 que comprende la secuencia de aminoacidos RASESVDSYGNSFMH (SEQ ID NO:30) o RASESVESYGSSFMH (SEQ ID NO:106), una region variable de cadena ligera CDR2 que comprende la secuencia de aminoacidos LTSNLES (SEQ ID NO:31) y una region variable de cadena ligera CDR3 que comprende la secuencia de aminoacidos QQNNEDPFT (SEQ ID NO:32). Tambien se refiere a una composicion farmaceutica. Dicho agente de union se unes especificamente al transcrito 3 similar a la inmunoglobulina humana (ILT3), siendo util en el tratamiento del cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950434P | 2019-12-19 | 2019-12-19 | |
| PCT/US2020/065642 WO2021127200A1 (en) | 2019-12-19 | 2020-12-17 | Ilt3-binding agents and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221263A1 true PE20221263A1 (es) | 2022-08-16 |
Family
ID=74554203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001110A PE20221263A1 (es) | 2019-12-19 | 2020-12-17 | Agentes de union a ilt3 y metodos de uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11760802B2 (es) |
| EP (1) | EP4077394A1 (es) |
| JP (1) | JP2023507110A (es) |
| KR (1) | KR20220130671A (es) |
| CN (2) | CN115746138A (es) |
| AR (1) | AR120822A1 (es) |
| AU (1) | AU2020405036A1 (es) |
| BR (1) | BR112022011790A2 (es) |
| CA (1) | CA3164642A1 (es) |
| CL (1) | CL2022001622A1 (es) |
| CO (1) | CO2022008272A2 (es) |
| IL (1) | IL293869A (es) |
| MX (1) | MX2022007288A (es) |
| PE (1) | PE20221263A1 (es) |
| TW (1) | TW202136304A (es) |
| WO (1) | WO2021127200A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022318734A1 (en) * | 2021-07-28 | 2024-02-08 | Merck Sharp & Dohme Llc | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies |
| US20230220076A1 (en) * | 2021-12-21 | 2023-07-13 | Ngm Biopharmaceuticals, Inc. | Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody |
| WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
| WO2023168455A2 (en) * | 2022-03-04 | 2023-09-07 | D2M Biotherapeutics Limited | Anti-lilrb1/2 antibodies and uses thereof |
| TW202346337A (zh) | 2022-03-29 | 2023-12-01 | 美商恩格姆生物製藥公司 | Ilt3及cd3結合劑以及其使用方法 |
| WO2023209716A1 (en) | 2022-04-25 | 2023-11-02 | Biond Biologics Ltd. | Anti-ilt3 antibodies and use thereof |
| WO2023235699A1 (en) * | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0644877B2 (ja) | 1986-12-26 | 1994-06-15 | 寳酒造株式会社 | 抗ヒト・フイブロネクチンモノクロ−ナル抗体 |
| US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US20040241167A1 (en) | 2001-06-25 | 2004-12-02 | Nicole Suciu-Foca | Ilt3 and ilt4-related compositons and methods |
| WO2003000199A2 (en) | 2001-06-25 | 2003-01-03 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
| US20070166318A1 (en) | 2003-05-30 | 2007-07-19 | Macina Roberto A | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| AU2005289664A1 (en) | 2004-09-24 | 2006-04-06 | Bioxell S.P.A. | 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof |
| ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
| WO2007089945A2 (en) | 2006-02-02 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Treating diseases by targeting silt3 |
| EP2041180B8 (en) | 2006-06-19 | 2014-03-05 | Liquidating Trust | Ilt3 binding molecules and uses therefor |
| WO2013033734A1 (en) | 2011-09-02 | 2013-03-07 | The Trustees Of Columbia University In The City Of New York | Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand |
| WO2013181438A2 (en) | 2012-05-30 | 2013-12-05 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating pro-inflammatory immune response |
| CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| LT2992017T (lt) | 2013-05-02 | 2021-02-25 | Anaptysbio, Inc. | Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1) |
| AU2015319809B2 (en) | 2014-09-28 | 2020-02-06 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| MX2017003478A (es) | 2014-11-05 | 2018-02-01 | Genentech Inc | Anticuerpos anti-fgfr2/3 y metodos para su uso. |
| CA2976130A1 (en) | 2015-02-11 | 2016-08-18 | University Health Network | Methods and compositions for modulating lilr proteins |
| KR102129107B1 (ko) | 2015-03-06 | 2020-07-02 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도 |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| JP2018025554A (ja) | 2016-07-29 | 2018-02-15 | 国立大学法人東北大学 | 炎症性疾患のマーカー |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018089300A1 (en) | 2016-11-10 | 2018-05-17 | Merck Sharp & Dohme Corp. | Ilt3 ligand |
| CA3053164A1 (en) | 2017-02-09 | 2018-08-16 | Bluefin Biomedicine, Inc. | Anti-ilt3 antibodies and antibody drug conjugates |
| CN111032025A (zh) | 2017-06-20 | 2020-04-17 | 居里研究所 | Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途 |
| SG11202004426SA (en) | 2017-11-17 | 2020-06-29 | Merck Sharp & Dohme | Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof |
| CN111867614A (zh) | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | 抗lilrb抗体及其用途 |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| CA3147182A1 (en) | 2019-08-13 | 2021-02-18 | Tohoku University | Novel immune checkpoint inhibitors and uses thereof |
-
2020
- 2020-12-17 MX MX2022007288A patent/MX2022007288A/es unknown
- 2020-12-17 BR BR112022011790A patent/BR112022011790A2/pt unknown
- 2020-12-17 CN CN202211579747.8A patent/CN115746138A/zh active Pending
- 2020-12-17 PE PE2022001110A patent/PE20221263A1/es unknown
- 2020-12-17 EP EP20851260.8A patent/EP4077394A1/en active Pending
- 2020-12-17 JP JP2022536551A patent/JP2023507110A/ja active Pending
- 2020-12-17 WO PCT/US2020/065642 patent/WO2021127200A1/en active Application Filing
- 2020-12-17 IL IL293869A patent/IL293869A/en unknown
- 2020-12-17 KR KR1020227019891A patent/KR20220130671A/ko unknown
- 2020-12-17 CA CA3164642A patent/CA3164642A1/en active Pending
- 2020-12-17 AU AU2020405036A patent/AU2020405036A1/en active Pending
- 2020-12-17 US US17/125,734 patent/US11760802B2/en active Active
- 2020-12-17 CN CN202080087154.2A patent/CN114901691A/zh active Pending
- 2020-12-18 AR ARP200103556A patent/AR120822A1/es unknown
- 2020-12-18 TW TW109144849A patent/TW202136304A/zh unknown
-
2022
- 2022-06-13 CO CONC2022/0008272A patent/CO2022008272A2/es unknown
- 2022-06-15 CL CL2022001622A patent/CL2022001622A1/es unknown
-
2023
- 2023-08-02 US US18/364,285 patent/US20240043533A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022001622A1 (es) | 2023-03-24 |
| BR112022011790A2 (pt) | 2022-08-30 |
| AU2020405036A1 (en) | 2022-07-07 |
| CO2022008272A2 (es) | 2022-08-30 |
| CN115746138A (zh) | 2023-03-07 |
| US20210221887A1 (en) | 2021-07-22 |
| EP4077394A1 (en) | 2022-10-26 |
| AR120822A1 (es) | 2022-03-23 |
| KR20220130671A (ko) | 2022-09-27 |
| MX2022007288A (es) | 2022-07-12 |
| TW202136304A (zh) | 2021-10-01 |
| US11760802B2 (en) | 2023-09-19 |
| IL293869A (en) | 2022-08-01 |
| CA3164642A1 (en) | 2021-06-24 |
| WO2021127200A8 (en) | 2022-07-14 |
| US20240043533A1 (en) | 2024-02-08 |
| WO2021127200A1 (en) | 2021-06-24 |
| CN114901691A (zh) | 2022-08-12 |
| JP2023507110A (ja) | 2023-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| PE20201183A1 (es) | Proteinas trispecificas y metodos de uso | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| RS53924B1 (en) | NOTCH-BINDING AGENTS AND ANTAGONISTS AND PROCEDURES FOR THEIR USE | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
| PE20120306A1 (es) | Anticuerpos anti-egfr y vectores que los codifican | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| RS53318B (en) | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | |
| PE20050712A1 (es) | Anticuerpos rg1 | |
| PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos |